# Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

> **NCT06160609** · PHASE1,PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 9 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Belantamab Mafodotin
- **DRUG:** GSK3174998

## Key facts

- **NCT ID:** NCT06160609
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-07
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of efficacy.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160609, "Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06160609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*